Results of AGM

Sareum Holdings PLC

14 December 2023

 

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 14 December 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, held its Annual General Meeting ("AGM") today and all resolutions were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the Company by way of proxy.

Details of the proxy voting results are shown in the table below. 

Ordinary Resolutions	Votes For	%	Votes Against	%	Votes Total	% of ISC Voted	Votes Withheld
1. Receive the financial statements for the year	4,955,805	99.3%	33,480	0.7%	4,989,285	7.1%	2,917
2. Receive and approve the Directors' Renumeration Report for the year	4,797,240	96.2%	187,995	3.8%	4,985,235	7.1%	6,967
3. Re-elect Dr Timothy Mitchell as Director of the Company	4,723,539	94.9%	256,139	5.1%	4,979,678	7.1%	12,524
4. Re-elect Dr Stephen Parker as Director of the Company	4,569,986	92.0%	399,292	8.0%	4,969,278	7.1%	22,924
5. Re-appoint Shipleys LLP as auditor	4,855,004	98.1%	92,757	1.9%	4,947,761	7.0%	44,441
6. Authorise the audit committee to determine auditor renumeration	4,867,151	98.3%	86,553	1.7%	4,953,704	7.1%	38,498
7. Directors' authority to allot new shares	4,567,808	92.4%	373,843	7.6%	4,941,651	7.0%	50,551
Special Resolution
8. Directors' authority to disapply pre-emption rights	4,573,097	92.5%	368,554	7.5%	4,941,651	7.0%	50,551
9. Authority to hold general meetings	4,926,142	99.0%	49,243	1.0%	4,975,385	7.1%	16,817

ISC - Issued Share Capital

The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website (www.sareum.com/investors)

For further information, please contact: 

Sareum Holdings plc Tim Mitchell, CEO Lauren Williams, Head of Investor Relations	01223 497700 [e-mail]
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman	020 7409 3494
Peel Hunt LLP (Joint Corporate Broker) James Steel / Patrick Birkholm	020 7418 8900
Hybridan LLP (Joint Corporate Broker) Claire Noyce ICR Consilium (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki	020 3764 2341 020 3709 5700

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

- Ends -

 

END